Varun Sriram 
Dealstreet

JSA advises Levim Lifetech on sale of 30% stake to Eris Lifesciences

The acquisition is aimed at expansion of Levim Lifetech's biotechnology footprint across a wide range of products and technologies.

Bar & Bench

JSA Advocates & Solicitors advised Levim Lifetech Limited on the sale of a 30% stake to Eris Lifesciences Limited for an investment of ₹54 crore

JSA advised Levim Lifetech on this transaction.

The transaction team was led by Varun Sriram (Partner) with support from Bharkavi S (Senior Associate), Associates Nithyashree Venkatesh, Maheema Senthilkumar & Sudha Putrevu.

The acquisition is aimed at expansion of Levim Lifetech's biotechnology footprint across a wide range of products and technologies.

Eris Lifesciences Ltd, established in 2007 and headquartered in Ahmedabad, India, is a publicly listed pharmaceutical company specializing in domestic branded formulations. The company focuses on chronic and sub-chronic lifestyle-related therapies, including anti-diabetes, cardiology, nutrition, and neuropsychiatry.

Levim Lifetech Pvt Ltd is an Indian biotechnology company specializing in the development and commercialization of biopharmaceutical products. The company focuses on leveraging cutting-edge science to bring evidence-based therapies to the market.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Arvind Kejriwal moves Supreme Court to transfer excise policy case from Justice Swarana Kanta Sharma

Removal of directors and the limits of board supremacy

SAM advises Anzen India on acquisition of majority stake in 12 Solar Portfolio SPVs

CMS INDUSLAW advises Swara Baby Products on acquisition of KA Enterprises, Solis Hygiene

Delhi High Court denies Arvind Kejriwal’s request to transfer excise policy case from Justice Swarana Kanta Sharma

SCROLL FOR NEXT